Immuneering Corporation
General ticker "IMRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $113.1M (TTM average)
Immuneering Corporation follows the US Stock Market performance with the rate: 48.8%.
Estimated limits based on current volatility of 3.4%: low 6.56$, high 7.03$
Factors to consider:
- Total employees count: 68 (-6.8%) as of 2023
- Top business risk factors: Regulatory and compliance, Product development risks, Supply chain disruptions, Intellectual property risks, Cybersecurity threats
- Current price 70.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.34$, 3.92$]
- 2025-12-31 to 2026-12-31 estimated range: [1.28$, 3.73$]
Financial Metrics affecting the IMRX estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -87.49 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 78.51 > 63.39
- Positive: Investing cash flow per share per price, % of 42.05 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
Short-term IMRX quotes
Long-term IMRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.32MM | $0.00MM | $0.00MM |
| Operating Expenses | $52.06MM | $58.41MM | $64.07MM |
| Operating Income | $-51.74MM | $-58.41MM | $-64.07MM |
| Non-Operating Income | $1.23MM | $4.94MM | $3.03MM |
| R&D Expense | $36.27MM | $41.62MM | $47.96MM |
| Income(Loss) | $-50.51MM | $-53.47MM | $-61.04MM |
| Profit(Loss)* | $-50.51MM | $-53.47MM | $-61.04MM |
| Stockholders Equity | $109.85MM | $90.58MM | $41.39MM |
| Assets | $122.37MM | $102.58MM | $52.71MM |
| Operating Cash Flow | $-44.10MM | $-48.97MM | $-55.00MM |
| Capital expenditure | $0.74MM | $0.34MM | $0.08MM |
| Investing Cash Flow | $41.83MM | $7.30MM | $26.43MM |
| Financing Cash Flow | $0.02MM | $28.44MM | $5.30MM |
| Earnings Per Share** | $-1.91 | $-1.88 | $-2.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.